辛伐他汀联合阿魏酸钠治疗早期糖尿病肾病的疗效观察

目的探讨辛伐他汀联合阿魏酸钠治疗早期糖尿病肾病（DN）的临床疗效。方法将106例DN患者采用数字表法随机分为两组，每组各53例，在均采取常规治疗基础上，对照组给予辛伐他汀，观察组采取辛伐他汀联合阿魏酸钠治疗，比较两组临床治疗效果。结果观察组总有效率为92．45％，显著高于对照组的73．58％（χ2=8．992，P〈0．05）；观察组24h尿微量白蛋白（Upro）、Cr、BUN及CRP水平分别为（50．72±7．74）mg／24h、（70．01±8．56）μmol／L、（3．87±0．54）mmol／L和（3．51±0．63）mmol／L，均显著低于对照组的（83．74±7．92）mg／24h、（84．33±9．01）μmol／L、（5．03±0．62）mmol／L和（5．52±0．61）mmol／L，差异均有统计学意义（t=7．73、6．59、8．62、9．30，均P〈0．05）。结论辛伐他汀联合阿魏酸钠治疗早期糖尿病肾病疗效显著，可有效改善患者临床症状，保护其肾功能，具有较好的临床应用价值。

The clinical effect of simvastatin combined with ferulate in treatment of early diabetic nephropathy

Objective To investigate the clinical efficacy of simvastatin combined with ferulate in treatment of early diabetic nephropathy （DN）. Methods 106 patients with DN were randomly divided into two groups by ran- dom number table, and each group had 53 cases. The control group was given simvastatin, while the observation group was given simvastatin combined with ferulate, and the clinical outcomes were compared between the two groups. Results The total effective rate of the observation group was 92.45%, which was significantly higher than 73.58% of the control group （ χ2 = 8. 992, P 〈 0.05 ） ; after treatment, the Upro, SCr, BUN and CRP levels of the observation group were （50.72 ± 7.74） mg/24h, （ 70.01 ± 8.56 ）μmoL/L, （ 3.87 ± 0.54 ） mmol/L and （ 3.51 ± 0.63 ） mmol/L, which were significantly lower than （ 83.74 ± 7.92 ） mg/24h, （ 84.33 ± 9.01 ）μmol/L, （ 5.03 ± 0.62 ） mmol/L and （ 5.52 ± 0.61 ） mmol/L of the control group,the difference was statistically significant （ t = 7.73,6.59,8.62,9.30, all P 〈 0.05 ）. Conclusion Simvastatin combined with ferulate in treatment of early diabetic nephropathy （DN） has significant effect ,and it can effectively improve the clinical symptoms and protect renal function, and it has better clinical value.